Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer

References

• Mullard A. The cancer vaccine resurgence. Nat Rev Drug Discov 2016; 15:663-5; PMID:27681782; https://doi.org/10.1038/nrd.2016.201
   PubMed Web of Science ®Google Scholar
• Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wölfel C, Huber C, Wölfel T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A 2005; 102:16013-8; PMID:16247014; https://doi.org/10.1073/pnas.0500090102
   PubMed Web of Science ®Google Scholar
• Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, et al. The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323-37; PMID:19723653; https://doi.org/10.1158/1078-0432.CCR-09-0737
   PubMed Web of Science ®Google Scholar
• Wang RF, Wang HY. Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res 2017; 27:11-37; PMID:28025978; https://doi.org/10.1038/cr.2016.155
   PubMed Web of Science ®Google Scholar
• Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM. Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol 2011; 18:23-34; PMID:21048000; https://doi.org/10.1128/CVI.00286-10
   PubMed Web of Science ®Google Scholar
• Tagliamonte M, Petrizzo A, Tornesello ML, Buonaguro FM, Buonaguro L. Antigen-specific vaccines for cancer treatment. Hum Vaccin Immunother 2014; 10:3332-46; PMID:25483639; https://doi.org/10.4161/21645515.2014.973317
   PubMed Web of Science ®Google Scholar
• Tomlinson IP, Novelli MR, Bodmer WF. The mutation rate and cancer. Proc Natl Acad Sci U S A 1996; 93:14800-3; PMID:8962135; https://doi.org/10.1073/pnas.93.25.14800
   PubMed Web of Science ®Google Scholar
• Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499:214-8; PMID:23770567; https://doi.org/10.1038/nature12213
   PubMed Web of Science ®Google Scholar
• Savage PA. Tumor antigenicity revealed. Trends Immunol 2014; 35:47-8; PMID:24439426; https://doi.org/10.1016/j.it.2014.01.001
   PubMed Web of Science ®Google Scholar
• Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 2016; 375:819-29; PMID:27433843; https://doi.org/10.1056/NEJMoa1604958
   PubMed Web of Science ®Google Scholar
• Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov 2017; 7(3):264–276; PMID:28031159; https://doi.org/10.1158/2159-8290.CD-16-0828
   PubMed Web of Science ®Google Scholar
• Tokheim C, Bhattacharya R, Niknafs N, Gygax DM, Kim R, Ryan M, Masica DL, Karchin R. Exome-Scale discovery of hotspot mutation regions in human cancer using 3D protein structure. Cancer Res 2016; 76:3719-31; PMID:27197156; https://doi.org/10.1158/0008-5472.CAN-15-3190
   PubMed Web of Science ®Google Scholar
• Chang MT, Asthana S, Gao SP, Lee BH, Chapman JS, Kandoth C, Gao J, Socci ND, Solit DB, Olshen AB, et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol 2016; 34:155-63; PMID:26619011; https://doi.org/10.1038/nbt.3391
   PubMed Web of Science ®Google Scholar
• Hundal J, Carreno BM, Petti AA, Linette GP, Griffith OL, Mardis ER, Griffith M. pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens. Genome Med 2016; 8:11; PMID:26825632; https://doi.org/10.1186/s13073-016-0264-5
   PubMed Web of Science ®Google Scholar
• Gubin MM, Artyomov MN, Mardis ER, Schreiber RD. Tumor neoantigens: Building a framework for personalized cancer immunotherapy. J Clin Invest 2015; 125:3413-21; PMID:26258412; https://doi.org/10.1172/JCI80008
   PubMed Web of Science ®Google Scholar
• http://www.parkerici.org/media/2016/parker-institute-for-cancer-immunotherapy-cri-neoantigen-alliance
   Google Scholar
• http://aperim.eu/downloads/publications
   Google Scholar
• Bassani-Sternberg M, Braunlein E, Klar R, Engleitner T, Sinitcyn P, Audehm S, Straub M, Weber J, Slotta-Huspenina J, Specht K, et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun 2016; 7:13404; PMID:27869121; https://doi.org/10.1038/ncomms13404
   PubMed Web of Science ®Google Scholar
• Gfeller D, Bassani-Sternberg M, Schmidt J, Luescher IF. Current tools for predicting cancer-specific T cell immunity. Oncoimmunology 2016; 5:e1177691; PMID:27622028; https://doi.org/10.1080/2162402X.2016.1177691
   PubMed Web of Science ®Google Scholar
• Hamburg MA. Paving the way for personalized medicine: FDA's role in a new era of medical product development. US Food Drug Admin 2013
   Google Scholar
• European Medicine Agency. Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells: EMA Committee for Advanced Therapies. London: European Medicine Agency; 2012.
   Google Scholar
• Ward A, Crow D. Race to control costs of cancer therapy revolution financial times. London: The Financial Times 2015
   Google Scholar
• Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, Meng M, Fritz D, Vascotto F, Hefesha H, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 2016; 534:396-401; PMID:27281205; https://doi.org/10.1038/nature18300
   PubMed Web of Science ®Google Scholar
• Castle JC, Kreiter S, Diekmann J, Lower M, van de Roemer N, de Graaf J, Selmi A, Diken M, Boegel S, Paret C, et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012; 72:1081-91; PMID:22237626; https://doi.org/10.1158/0008-5472.CAN-11-3722
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr., Yamshchikov G, Neese P, Galavotti H, Eastham S, Engelhard VH, Kittlesen D, Deacon D, Hibbitts S, Grosh WW, et al. Phase I trial of a melanoma vaccine with gp100(280–288) peptide and tetanus helper peptide in adjuvant: Immunologic and clinical outcomes. Clin Cancer Res 2001; 7:3012-24. PMID:11595689
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Clifton GT, Holmes JP, Schneble E, van Echo D, Ponniah S, Peoples GE. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol 2014; 25:1735-42; PMID:24907636; https://doi.org/10.1093/annonc/mdu211
   PubMed Web of Science ®Google Scholar
• Nishida S, Koido S, Takeda Y, Homma S, Komita H, Takahara A, Morita S, Ito T, Morimoto S, Hara K, et al. Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer. J Immunother 2014; 37:105-14; PMID:24509173; https://doi.org/10.1097/CJI.0000000000000020
   PubMed Web of Science ®Google Scholar
• Kotsakis A, Papadimitraki E, Vetsika EK, Aggouraki D, Dermitzaki EK, Hatzidaki D, Kentepozidis N, Mavroudis D, Georgoulias V. A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide. Lung Cancer 2014; 86:59-66; PMID:25130084; https://doi.org/10.1016/j.lungcan.2014.07.018
   PubMed Web of Science ®Google Scholar
• Okuno K, Sugiura F, Inoue K, Sukegawa Y. Clinical trial of a 7-peptide cocktail vaccine with oral chemotherapy for patients with metastatic colorectal cancer. Anticancer Res 2014; 34:3045-52. PMID:24922671
   PubMed Web of Science ®Google Scholar
• Weide B, Garbe C, Rammensee HG, Pascolo S. Plasmid DNA- and messenger RNA-based anti-cancer vaccination. Immunol Lett 2008; 115:33-42; PMID:18006079; https://doi.org/10.1016/j.imlet.2007.09.012
   PubMed Web of Science ®Google Scholar
• Graham BS, Enama ME, Nason MC, Gordon IJ, Peel SA, Ledgerwood JE, Plummer SA, Mascola JR, Bailer RT, Roederer M, et al. DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. PLoS One 2013; 8:e59340; PMID:23577062; https://doi.org/10.1371/journal.pone.0059340
   PubMed Web of Science ®Google Scholar
• Grodeland G, Fredriksen AB, Loset GA, Vikse E, Fugger L, Bogen B. Antigen targeting to human HLA class II molecules increases efficacy of DNA vaccination. J Immunol 2016; 197:3575-85; PMID:27671110; https://doi.org/10.4049/jimmunol.1600893
   PubMed Web of Science ®Google Scholar
• Kreiter S, Vormehr M, van de Roemer N, Diken M, Lower M, Diekmann J, Boegel S, Schrörs B, Vascotto F, Castle JC, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 2015; 520:692-6; PMID:25901682; https://doi.org/10.1038/nature14426
   PubMed Web of Science ®Google Scholar
• de Gruijl T, Santegoeds S, van Wetering S, Singh SK, Hall A, van de Loosdrecht AA, et al. Allogeneic dendritic cell (DC) vaccination as an “off the shelf” treatment to prevent or delay relapse in elderly acute myeloid leukemia patients: Results of Phase I/IIa safety and feasibility study. J Immunother Cancer 2013; 1:P205-P; ; https://doi.org/10.1186/2051-1426-1-S1-P205
   Google Scholar
• Kantor J, Irvine K, Abrams S, Kaufman H, DiPietro J, Schlom J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst 1992; 84:1084-91; PMID:1619682; https://doi.org/10.1093/jnci/84.14.1084
   PubMed Web of Science ®Google Scholar
• Larocca C, Schlom J. Viral vector-based therapeutic cancer vaccines. Cancer J 2011; 17:359-71; PMID:21952287; https://doi.org/10.1097/PPO.0b013e3182325e63
   PubMed Web of Science ®Google Scholar
• Toussaint B, Chauchet X, Wang Y, Polack B, Le Gouellec A. Live-attenuated bacteria as a cancer vaccine vector. Expert Rev Vaccines 2013; 12:1139-54; PMID:24124876; https://doi.org/10.1586/14760584.2013.836914
   PubMed Web of Science ®Google Scholar
• Mayr A, Munz E. [Changes in the vaccinia virus through continuing passages in chick embryo fibroblast cultures]. Zentralbl Bakteriol Orig 1964; 195:24-35. PMID:5890664
   PubMedGoogle Scholar
• Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schafer H, Holzner A. [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)]. Dtsch Med Wochenschr 1974; 99:2386-92; PMID:4426258; https://doi.org/10.1055/s-0028-1108143
   PubMed Web of Science ®Google Scholar
• Acres B, Bonnefoy JY. Clinical development of MVA-based therapeutic cancer vaccines. Expert Rev Vaccines 2008; 7:889-93; PMID:18767940; https://doi.org/10.1586/14760584.7.7.889
   PubMed Web of Science ®Google Scholar
• Farsaci B, Kwilas A, Hodge J. Design, development, and translation of poxvirus-based vaccines for cancer. In A Bot, M Obrocea, & F Marincola (Eds.), Cancer Vaccines: From Research to Clinical Practice (Vol. 1, pp. 56-77). London: Informa Healthcare; 2011.
   Google Scholar
• Mooij P, Balla-Jhagjhoorsingh SS, Koopman G, Beenhakker N, van Haaften P, Baak I, Nieuwenhuis IG, Kondova I, Wagner R, Wolf H, et al. Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates. J Virol 2008; 82:2975-88; PMID:18184713; https://doi.org/10.1128/JVI.02216-07
   PubMed Web of Science ®Google Scholar
• Galaine J, Borg C, Godet Y, Adotevi O. Interest of tumor-specific CD4 T helper 1 Cells for therapeutic anticancer vaccine. Vaccines (Basel) 2015; 3:490-502; PMID:26350591; https://doi.org/10.3390/vaccines3030490
   PubMed Web of Science ®Google Scholar
• Brun JL, Dalstein V, Leveque J, Mathevet P, Raulic P, Baldauf JJ, Scholl S, Huynh B, Douvier S, Riethmuller D, et al. Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am J Obstet Gynecol 2011; 204:169 e1-8; PMID:21284968; https://doi.org/10.1016/j.ajog.2010.09.020
   PubMed Web of Science ®Google Scholar
• Quoix E, Lena H, Losonczy G, Forget F, Chouaid C, Papai Z, Gervais R, Ottensmeier C, Szczesna A, Kazarnowicz A, et al. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): Results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. Lancet Oncol 2016; 17:212-23; PMID:26727163; https://doi.org/10.1016/S1470-2045(15)00483-0
   PubMed Web of Science ®Google Scholar
• Tosch C, Bastien B, Barraud L, Grellier B, Nourtier V, Gantzer M, et al. Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC. Submitted for publication; 2017
   Google Scholar
• Singh P, Pal SK, Alex A, Agarwal N. Development of PROSTVAC immunotherapy in prostate cancer. Future Oncol 2015; 11:2137-48; PMID:26235179; https://doi.org/10.2217/fon.15.120
   PubMed Web of Science ®Google Scholar
• Hardwick N, Chung V, Cristea M, Ellenhorn JD, Diamond DJ. Overcoming immunosuppression to enhance a p53MVA vaccine. Oncoimmunology 2014; 3:e958949; PMID:25941580; https://doi.org/10.4161/21624011.2014.958949
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: The cancer-immunity cycle. Immunity 2013; 39:1-10; PMID:23890059; https://doi.org/10.1016/j.immuni.2013.07.012
   PubMed Web of Science ®Google Scholar
• Breitbach CJ, Lichty BD, Bell JC. Oncolytic viruses: Therapeutics with an identity crisis. EBioMedicine 2016; 9:31-6; PMID:27407036; https://doi.org/10.1016/j.ebiom.2016.06.046
   PubMed Web of Science ®Google Scholar
• Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol 2009; 21:346-51; PMID:19500964; https://doi.org/10.1016/j.coi.2009.05.016
   PubMed Web of Science ®Google Scholar